---
title: "TPO-R agonists"
alias: TPO-RA
slug: "tpo-r-agonists"
date: "2023-06-20"
enableToc: false
tags:
  - building
---

> [!info]
>
> ðŸŒ± ä¾†è‡ªï¼š[[Second-line or maintainence therapy for idiopathic thrombocytopenic purpura]]

# TPO-R agonists

- having an overall response rate of âˆ¼75%
- a durable response rate (response at 6 months) of âˆ¼65%

## Drugs

- **Romiplostim**

  - **Route of administration**: Subcutaneous injections
  - **Mechanism of action**: TPO-RA
  - **Dosage**: 1-10 Âµg/kg once weekly
  - **Response rate**: Overall response of 75%; durable response at 6 months is 65%; 10% to 30% may achieve treatment remission
  - **Adverse effects**:
    - Headache
    - Muscle aches
    - Venous and arterial thromboembolism
    - Possible increase in bone marrow reticulin and collagen fibrosis

- **[[eltrombopag.md|Eltrombopag]]**

  - **Route of administration**: Oral (restricted diet)
  - **Mechanism of action**: TPO-RA
  - **Dosage**: 25-75 mg once daily
  - **Response rate**: Not specified
  - **Adverse effects**:
    - Headache
    - Venous and arterial thromboembolism
    - Elevated liver enzymes
    - Possible increase in bone marrow reticulin and collagen fibrosis

- **Avatrombopag**
  - **Route of administration**: Oral
  - **Mechanism of action**: TPO-RA
  - **Dosage**: 20-40 mg once daily
  - **Response rate**: 65% at day 8\*
  - **Adverse effects**:
    - Headaches
    - Arthralgia
    - Venous and arterial thromboembolism
